Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer

被引:143
作者
Hovens, Guido C.
Stokkel, Marcel P.
Kievit, Job
Corssmit, Eleonora P.
Pereira, Alberto M.
Romijn, Johannes A.
Smit, Johannes W. A.
机构
[1] Leiden Univ, Med Ctr, Dept Endocrinol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Metab Dis, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Nucl Med, NL-2300 RC Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.1210/jc.2006-2566
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The relation between serum TSH levels and risk for recurrence or thyroid carcinoma-related death in patients with differentiated thyroid carcinoma has only been studied to a limited extent. Design: We conducted a single-center observational study in 366 consecutive patients with differentiated thyroid carcinoma, who had all been treated according to the same protocol for initial therapy and follow-up. Median duration of follow-up was 8.85 yr. Methods: The relation between summarizing variables of unstimulated serum TSH concentrations (25th, 50th, and 75th percentiles, the percentage of suppressed and unsuppressed TSH values) and risk for recurrence or thyroid carcinoma-related death was analyzed by Cox survival analyses in patients with at least four TSH measurements. Results: In Cox regression analysis, we found a positive association between serum TSH concentrations and risk for thyroid carcinoma-related death and relapse, even in initially cured patients. The median of the individual TSH concentrations was the best indicator for thyroid carcinoma-related death (hazard ratio 2.03; confidence interval 1.22-3.37) and relapse (hazard ratio 1.41; confidence interval 1.03-1.95). A threshold of 2 mU/liter differentiated best between relapse-free survival and thyroid carcinoma-related death or relapse. Conclusion: Our study supports current guidelines, which advise to aim at TSH levels in the low normal range in cured low-risk patients, whereas TSH levels should be suppressed in noncured or high-risk patients.
引用
收藏
页码:2610 / 2615
页数:6
相关论文
共 24 条
[1]  
[Anonymous], TNM CLASSIFICATION M
[2]  
BALME HW, 1954, LANCET, V1, P812
[3]   Thyroid-hormone therapy and thyroid cancer: a reassessment [J].
Biondi, B ;
Filetti, S ;
Schlumberger, M .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2005, 1 (01) :32-40
[4]   Subclinical hyperthyroidism: clinical features and treatment options [J].
Biondi, B ;
Palmieri, EA ;
Klain, M ;
Schlumberger, M ;
Filetti, S ;
Lombardi, G .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (01) :1-9
[5]   HUMAN THYROID-CANCER - MEMBRANE THYROTROPIN BINDING AND ADENYLATE-CYCLASE ACTIVITY [J].
CARAYON, P ;
THOMASMORVAN, C ;
CASTANAS, E ;
TUBIANA, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1980, 51 (04) :915-920
[6]   CHARACTERIZATION OF THE THYROTROPIN RECEPTOR-ADENYLATE CYCLASE SYSTEM IN NEOPLASTIC HUMAN THYROID-TISSUE [J].
CLARK, OH ;
GEREND, PL ;
GORETZKI, P ;
NISSENSON, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 57 (01) :140-147
[7]   Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry [J].
Cooper, DS ;
Specker, B ;
Ho, M ;
Sperling, M ;
Ladenson, PW ;
Ross, DS ;
Ain, KB ;
Bigos, ST ;
Brierley, JD ;
Haugen, BR ;
Klein, I ;
Robbins, J ;
Sherman, SI ;
Taylor, T ;
Maxon, HR .
THYROID, 1998, 8 (09) :737-744
[8]   ENDOCRINE DEPENDENCY OF PAPILLARY CARCINOMAS OF THYROID [J].
CRILE, G .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1966, 195 (09) :721-&
[9]   THYROID-CARCINOMA WITH SPINAL-CORD COMPRESSION [J].
GOLDBERG, LD ;
DITCHEK, NT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1981, 245 (09) :953-954
[10]  
Goretzki P E, 1990, Recent Results Cancer Res, V118, P48